Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05430971 · ClinicalTrials.gov registry record
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
A clinical trial of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), sponsored by Immune Oncology Research Institute.
- Recruiting
- Registry status
- 200
- Enrollment target
- 20
- Study locations
NCT05430971: Recruiting study of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), sponsored by Immune Oncology Research Institute.
NCT05430971 is a study of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) that is actively recruiting participants, run by Immune Oncology Research Institute. The registered enrollment target is 200 participants. The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05430971, a study of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), is actively recruiting participants, sponsored by Immune Oncology Research Institute.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for international collaboration to collect data on BPDCN clinical presentations, diagnostics, treatment regimens and outcomes. Therefore, the objectives of this study are: (1) to build a large database of patients with BPDCN, (2) to investigate the characteristics and outcome of the disease with different treatment regimens, (3) to evaluate prognostic factors, and (4) to generate data-based prospective treatment recommendations.
Primary Outcome
Time from diagnosis to death
Conditions Studied
Study Locations (20)
Other
- Hematology Center named after prof. R. Yeolyan - Yerevan
- Cyprus Society of Haematology - Nicosia
- Oncology Center, Mansoura University Faculty of Medicine - Al Mansurah
- M. Iashvili Children's Central Hospital - Tbilisi
- Department of Medical Oncology, Dr. B.R.A Institute Rotary Cancer Hospital, All India Institute of Medical Sciences - New Delhi
- Pediatric Hematology Oncology, Children's Welfare Teaching Hospital, Medical City, College of Medicine, University of Baghdad - Baghdad
- University of Perugia - Azienda Ospedaliera Perugia - Perugia
- Department of Biomedicine and Prevention, University of Rome Tor Vergata - Roma
- Department of hematology, Kuwait Cancer Control Center - Kuwait City
- Fundeni Clinical Institute, Department of Acute Leukemia - Bucharest
- China Medical University Children's Hospital - Taichung
- Turkish Pediatric Cancer Registry - Ankara
- Istanbul University, Oncology Institute - Istanbul
- University of Health Sciences, Umraniye Research and Education Hospital, Pediatric Hematology and Oncology Department, Pediatric Bone Marrow Transplantation Unit - Istanbul
Florida
- Sylvester Comprehensive Cancer Center, University of Miami - Miami
- Moffitt Cancer Center - Tampa
Washington
- Seattle Children's Cancer and Blood Disorders Center - Seattle
Alberta
- University of Calgary - Calgary
Ontario
- Children's Hospital of Eastern Ontario, University of Ottawa - Ottawa
Essex
- Broomfield Hospital, Haematology Mid and South Essex University Hospitals Group - Chelmsford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2032-07 |
What NCT05430971 shows while recruiting
NCT05430971 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) appearing as the primary indexed condition, and to 0 interventions.
NCT05430971 names 20 study sites across 6 states, led by Other, Florida, Washington.
Frequently Asked Questions
What is clinical trial NCT05430971 about?
NCT05430971 is a clinical study titled "Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry". Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for intern...
What is the current status of trial NCT05430971?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2022-07-01. Estimated completion is 2032-07.
What conditions does trial NCT05430971 study?
This clinical trial studies the following conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Who is sponsoring clinical trial NCT05430971?
This trial is sponsored by Immune Oncology Research Institute, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05430971 being conducted?
This trial has 20 study locations across Florida, Washington, Alberta, Ontario, Essex. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI